MAGI-2是前列腺腺癌的一种敏感且特异的标志物：与AMACR的比较。

MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma: A Comparison With AMACR.

作者信息

Goldstein Jeffery, Goyal Rajen, Roland Joseph T, Gellert Lan L, Clark Peter E, Hameed Omar, Giannico Giovanna A

机构信息

From the Department of Pathology, Microbiology, and Immunology.

Department of Surgery.

出版信息

Am J Clin Pathol. 2016 Sep;146(3):294-302. doi: 10.1093/ajcp/aqw111.

DOI:10.1093/ajcp/aqw111

PMID:27543977

Abstract

OBJECTIVES

We compared the utility of membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2) and α-methylacyl CoA (AMACR) by immunohistochemistry in diagnosing prostatic adenocarcinoma.

METHODS

Seventy-eight radical prostatectomies were used to construct three tissue microarrays with 512 cores, including benign prostatic tissue, benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia (HGPIN), and adenocarcinoma. AMACR and MAGI-2 immunohistochemistry were evaluated by visual and image analysis.

RESULTS

MAGI-2 and AMACR were significantly higher in adenocarcinoma and HGPIN compared with benign tissue. At H-score cutoffs of 300 and 200, MAGI-2 was more accurate in distinguishing benign from malignant glands than AMACR. Areas under the curve by image and visual analysis were 0.846 and 0.818 for MAGI-2 and 0.937 and 0.924 for AMACR, respectively. The accuracy of MAGI-2 in distinguishing benign from malignant glands on the same core was higher (95% vs 88%).

CONCLUSIONS

MAGI-2 could represent a useful adjunct for diagnosis of prostatic adenocarcinoma, especially when AMACR is not discriminatory.

摘要

目的

我们通过免疫组织化学比较了含膜相关鸟苷酸激酶、WW和PDZ结构域蛋白2（MAGI-2）与α-甲基酰基辅酶A（AMACR）在诊断前列腺腺癌中的效用。

方法

使用78例根治性前列腺切除术构建包含512个芯块的三个组织微阵列，包括良性前列腺组织、良性前列腺增生、高级别前列腺上皮内瘤变（HGPIN）和腺癌。通过视觉和图像分析评估AMACR和MAGI-2免疫组织化学。

结果

与良性组织相比，MAGI-2和AMACR在腺癌和HGPIN中显著更高。在H评分临界值为300和200时，MAGI-2在区分良性和恶性腺体方面比AMACR更准确。通过图像和视觉分析得到的曲线下面积，MAGI-2分别为0.846和0.818，AMACR分别为0.937和0.924。MAGI-2在同一芯块上区分良性和恶性腺体的准确性更高（95%对88%）。